New Two-Antibody cocktail takes on Hard-to-Treat HER2 cancers
NCT ID NCT07646626
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This Phase 2 study is testing a combination of two experimental antibodies (SSGJ-705 and SSGJ-612), with or without chemotherapy, in people with advanced HER2-expressing solid tumors that cannot be removed by surgery or have spread. The goal is to see if the treatment can shrink tumors and how safe it is. About 150 adults with certain cancers (like colorectal, bladder, breast, bile duct, or stomach cancer) are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SSGJ-705 (a bispecific antibody targeting PD-1 and HER2) plus SSGJ-612 (an anti-HER2 antibody), with or without chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced HER2-expressing cancers that have stopped responding to standard therapy.
What could go wrong
This is an early Phase 2 study with only 150 participants, so results may not apply to everyone. Side effects from the antibodies and chemotherapy could be serious, and the treatment may not shrink tumors or improve survival.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.